Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.

Haemel AK, O'Brian AL, Teng JM.

Arch Dermatol. 2010 Jul;146(7):715-8. doi: 10.1001/archdermatol.2010.125. No abstract available.

PMID:
20644030
2.

Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.

DeKlotz CM, Ogram AE, Singh S, Dronavalli S, MacGregor JL.

Arch Dermatol. 2011 Sep;147(9):1116-7. doi: 10.1001/archdermatol.2011.254. No abstract available.

PMID:
21931059
3.

A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.

Wheless JW, Almoazen H.

J Child Neurol. 2013 Jul;28(7):933-6. doi: 10.1177/0883073813488664. Epub 2013 May 16.

PMID:
23680945
4.

[Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].

Cuevas Asencio I, Albornoz López R, Salido Vallejo R, Reyes Malia M.

Farm Hosp. 2012 Sep-Oct;36(5):433-4. doi: 10.1016/j.farma.2011.09.006. Epub 2012 Jul 31. Spanish. No abstract available.

PMID:
22858090
5.

A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.

Wataya-Kaneda M, Tanaka M, Nakamura A, Matsumoto S, Katayama I.

Br J Dermatol. 2011 Oct;165(4):912-6. doi: 10.1111/j.1365-2133.2011.10471.x.

PMID:
21692771
6.

[Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].

Tiedemann Svendsen M, Bygum A, Hansen LK, Broesby-Olsen S.

Ugeskr Laeger. 2013 Oct 21;175(43):2569-70. Danish.

PMID:
24629155
7.

Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.

Mutizwa MM, Berk DR, Anadkat MJ.

Br J Dermatol. 2011 Oct;165(4):922-3. doi: 10.1111/j.1365-2133.2011.10476.x. No abstract available.

PMID:
21692776
8.

Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.

Knöpfel N, Martín-Santiago A, Bauza A, Hervás JA.

Actas Dermosifiliogr. 2014 Oct;105(8):802-3. doi: 10.1016/j.ad.2013.09.013. Epub 2013 Dec 17. English, Spanish. No abstract available.

PMID:
24355193
9.

Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.

Koenig MK, Hebert AA, Roberson J, Samuels J, Slopis J, Woerner A, Northrup H.

Drugs R D. 2012 Sep 1;12(3):121-6. doi: 10.2165/11634580-000000000-00000.

10.

Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.

Balestri R, Neri I, Patrizi A, Angileri L, Ricci L, Magnano M.

J Eur Acad Dermatol Venereol. 2015 Jan;29(1):14-20. doi: 10.1111/jdv.12665. Epub 2014 Aug 29. Review.

PMID:
25174683
11.

First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.

Tanaka M, Wataya-Kaneda M, Nakamura A, Matsumoto S, Katayama I.

Br J Dermatol. 2013 Dec;169(6):1314-8. doi: 10.1111/bjd.12567.

PMID:
23909960
12.

Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.

Tu J, Foster RS, Bint LJ, Halbert AR.

Australas J Dermatol. 2014 Feb;55(1):63-9. doi: 10.1111/ajd.12125. Epub 2013 Dec 22.

PMID:
24359523
13.

The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.

Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL.

Br J Dermatol. 2008 Aug;159(2):473-5. doi: 10.1111/j.1365-2133.2008.08677.x. Epub 2008 Jun 28.

PMID:
18547304
14.

Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.

Foster RS, Bint LJ, Halbert AR.

Australas J Dermatol. 2012 Feb;53(1):52-6. doi: 10.1111/j.1440-0960.2011.00837.x. Epub 2011 Dec 29.

PMID:
22309333
15.

[Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].

Valerón-Almazán P, Vitiello M, Abuchar A, Kerdel FA.

Actas Dermosifiliogr. 2012 Mar;103(2):165-6. doi: 10.1016/j.ad.2011.02.019. Epub 2011 Aug 20. Spanish. No abstract available.

PMID:
21861956
16.

Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin.

Kaufman McNamara E, Curtis AR, Fleischer AB Jr.

J Dermatolog Treat. 2012 Feb;23(1):46-8. doi: 10.3109/09546634.2010.489598. Epub 2010 Aug 1.

PMID:
20673154
17.

Targeted topical and combination laser surgery for the treatment of angiofibromas.

Bae-Harboe YS, Geronemus RG.

Lasers Surg Med. 2013 Nov;45(9):555-7. doi: 10.1002/lsm.22189.

PMID:
24136238
18.

Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.

Dill PE, De Bernardis G, Weber P, Lösch U.

Pediatr Neurol. 2014 Jul;51(1):109-13. doi: 10.1016/j.pediatrneurol.2014.02.016. Epub 2014 Mar 1.

PMID:
24810875
19.

Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.

Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, Ruano J, Galán-Gutierrez M, Vélez A, Moreno-Giménez JC.

J Eur Acad Dermatol Venereol. 2012 Oct;26(10):1315-8. doi: 10.1111/j.1468-3083.2011.04212.x. Epub 2011 Aug 11.

PMID:
21834948
20.

Unilateral facial angiofibromas--a segmental form of tuberous sclerosis.

McGrae JD Jr, Hashimoto K.

Br J Dermatol. 1996 Apr;134(4):727-30.

PMID:
8733380
Items per page

Supplemental Content

Write to the Help Desk